Last updated: 2026-09-06 12:37:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
TScan Therapeutics, Inc. (TCRX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.40, with a market capitalization of $25.83M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.35 to $2.57. This page covers its latest market performance, valuation, price trends and company information.
$25.83M | |
$0.37 | |
$26.80 | |
$0.35 | |
$0.37 | |
1.63M | |
-- | |
-- | |
$2.57 | |
$0.35 | |
-- | |
-- |
TScan Therapeutics, Inc. (TCRX) last closed at $0.37 as of 2026-09-04 23:51:00, unchanged from the previous close of $0.37.
During the latest regular trading session, TCRX traded between $0.35 and $26.80, with a volume of 1.63M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, TScan Therapeutics, Inc. (TCRX) moved from $0.75 to $0.40, representing a decline of 47.33% ($0.36).
The stock traded between $0.37 and $0.41 during the period. The latest price is near the upper end of the 7-day range, indicating strong downward.
The average daily volume was 2.12 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2.0%
TCRX is currently trading at $0.40, placing it 2.0% of the way from its 52-week low of $0.35 to its 52-week high of $2.57. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 142 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of TScan Therapeutics, Inc. (TCRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.